Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroscience
Pharma
Even through its remake, Alkermes retains upward trajectory: CEO
Alkermes is showcasing its rare set of attributes as a pure-play neuroscience biotech that is self-funded and has an intriguing pipeline program.
Kevin Dunleavy
Jan 13, 2025 7:36am
A revival in neuro therapeutics
Oct 11, 2024 8:37am
BMS wins FDA approval for new schizophrenia med Cobenfy
Sep 26, 2024 7:38pm
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
JPM24: Alkermes ready to roll as pure-play neuroscience company
Jan 10, 2024 9:04am
Biogen's Alzheimer's sales are negative early in Leqembi launch
Apr 25, 2023 11:40am
